CRSP
Price
$61.67
Change
+$1.35 (+2.24%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
5.49B
33 days until earnings call
LGND
Price
$169.62
Change
+$2.86 (+1.72%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
3.25B
40 days until earnings call
Interact to see
Advertisement

CRSP vs LGND

Header iconCRSP vs LGND Comparison
Open Charts CRSP vs LGNDBanner chart's image
CRISPR Therapeutics AG
Price$61.67
Change+$1.35 (+2.24%)
Volume$61.87K
Capitalization5.49B
Ligand Pharmaceuticals
Price$169.62
Change+$2.86 (+1.72%)
Volume$1.7K
Capitalization3.25B
CRSP vs LGND Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. LGND commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Buy and LGND is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (CRSP: $60.32 vs. LGND: $166.76)
Brand notoriety: CRSP and LGND are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 70% vs. LGND: 41%
Market capitalization -- CRSP: $5.49B vs. LGND: $3.25B
CRSP [@Biotechnology] is valued at $5.49B. LGND’s [@Biotechnology] market capitalization is $3.25B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileLGND’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • LGND’s FA Score: 0 green, 5 red.
According to our system of comparison, LGND is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 5 TA indicator(s) are bullish while LGND’s TA Score has 2 bullish TA indicator(s).

  • CRSP’s TA Score: 5 bullish, 5 bearish.
  • LGND’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than LGND.

Price Growth

CRSP (@Biotechnology) experienced а -4.16% price change this week, while LGND (@Biotechnology) price change was -1.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +9.50%, and the average quarterly price growth was +52.01%.

Reported Earning Dates

CRSP is expected to report earnings on Oct 29, 2025.

LGND is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($5.49B) has a higher market cap than LGND($3.25B). LGND (55.632) and CRSP (53.252) have similar YTD gains . LGND has higher annual earnings (EBITDA): -45.94M vs. CRSP (-533.5M). CRSP has more cash in the bank: 1.72B vs. LGND (255M). LGND has less debt than CRSP: LGND (5.74M) vs CRSP (215M). LGND has higher revenues than CRSP: LGND (188M) vs CRSP (35M).
CRSPLGNDCRSP / LGND
Capitalization5.49B3.25B169%
EBITDA-533.5M-45.94M1,161%
Gain YTD53.25255.63296%
P/E RatioN/A46.19-
Revenue35M188M19%
Total Cash1.72B255M675%
Total Debt215M5.74M3,744%
FUNDAMENTALS RATINGS
CRSP vs LGND: Fundamental Ratings
CRSP
LGND
OUTLOOK RATING
1..100
6462
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
10039
SMR RATING
1..100
9694
PRICE GROWTH RATING
1..100
4039
P/E GROWTH RATING
1..100
7690
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (64) in the Biotechnology industry is in the same range as LGND (72). This means that CRSP’s stock grew similarly to LGND’s over the last 12 months.

LGND's Profit vs Risk Rating (39) in the Biotechnology industry is somewhat better than the same rating for CRSP (100). This means that LGND’s stock grew somewhat faster than CRSP’s over the last 12 months.

LGND's SMR Rating (94) in the Biotechnology industry is in the same range as CRSP (96). This means that LGND’s stock grew similarly to CRSP’s over the last 12 months.

LGND's Price Growth Rating (39) in the Biotechnology industry is in the same range as CRSP (40). This means that LGND’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (76) in the Biotechnology industry is in the same range as LGND (90). This means that CRSP’s stock grew similarly to LGND’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPLGND
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
70%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 11 days ago
80%
Bullish Trend 16 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 2 days ago
72%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
68%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PPSRX20.73N/A
N/A
Principal Large Cap Value III R5
VALAX29.86N/A
N/A
Al Frank Adv
GGOAX13.38N/A
N/A
Goldman Sachs Mid Cap Growth A
DGEYX25.50N/A
N/A
BNY Mellon Global Emerging Mkts - Y
RNWBX89.55-0.71
-0.79%
American Funds New World R2

LGND and

Correlation & Price change

A.I.dvisor indicates that over the last year, LGND has been loosely correlated with AGIO. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if LGND jumps, then AGIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LGND
1D Price
Change %
LGND100%
-1.30%
AGIO - LGND
49%
Loosely correlated
-1.90%
AXON - LGND
49%
Loosely correlated
+2.02%
CRSP - LGND
47%
Loosely correlated
-1.20%
SYRE - LGND
47%
Loosely correlated
-8.18%
ACLX - LGND
44%
Loosely correlated
-0.44%
More